Yayınlar & Eserler

Yayın Ağı
Makaleler 20
Tümü (20)
SCI-E, SSCI, AHCI (11)
SCI-E, SSCI, AHCI, ESCI (11)
Scopus (13)
TRDizin (7)
Diğer Yayınlar (2)

1. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

Sezgin Y., Karhan O., Aldemir M. N., Ürün M., Erçek B. M., Urakcı Z., et al.
Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier

2. Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study

Karhan O., İleri S., Urakçl Z., Arvas H., Klllç D. K., Sezgin Y., et al.
Oncology (Switzerland) , cilt.103, sa.6, ss.498-507, 2025 (SCI-Expanded, Scopus) identifier identifier

3. The Role of Bıomarkers In Predıctıng Neoadjuvant Treatment Response In Gastrıc Cancer

Sezgin Y., Ürün M.
Eastern Journal of Medicine , cilt.30, sa.2, ss.245-255, 2025 (Scopus, TRDizin) Creative Commons License identifier identifier

4. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

Karhan O., İleri S., Urakçı Z., Sezgin Y., Yıldırım Ü., Ünlü B., et al.
Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus) identifier identifier

5. Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients

Ürün M., Güner G., Sezgin Y., Uysal E., SAKİN A., Kilickap S.
Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus) identifier identifier

6. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience

Sezgin Y., Karhan O., Ileri S., Ebinc S., Tunc S., Urakci Z.
Journal of the College of Physicians and Surgeons Pakistan , cilt.34, sa.8, ss.904-909, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

7. Testis Kanserinde Prognostik Faktörler

Sezgin Y., Karhan O., Biçer A., İleri S., Yerlikaya H., Tunç S., et al.
Turkish Journal of Clinics and Laboratory , cilt.15, sa.2, ss.176-181, 2024 (TRDizin) Creative Commons License identifier

8. Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer

Karhan O., Sezgin Y., Ileri S., Tunc S.
Nigerian journal of clinical practice , cilt.27, sa.6, ss.800-803, 2024 (SCI-Expanded, Scopus) identifier identifier

9. Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Guner G., Sezgin Y.
Eurasian Journal of Medical Investigation , cilt.8, sa.1, ss.48-53, 2024 (TRDizin) identifier

10. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

Ürün M., Güner G., Sezgin Y., SAKİN A., Kılıçkap S.
Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus) identifier identifier

11. Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats

Sezgin Y., Bora E. S., Arda D. B., UYANIKGİL Y., Erbaş O.
Acta cirurgica brasileira , cilt.39, 2024 (SCI-Expanded, Scopus) identifier identifier

12. The impact of timing adjuvant therapy on disease-free survival among patients with stage iib-iiia non-small cell lung cancer receiving platinum- based treatment

ÜRÜN M., SEZGİN Y., UYSAL E.
Turkish Journal of Clinics and Laboratory , cilt.14, sa.3, ss.639-644, 2023 (TRDizin) identifier

13. Comparison of the Efficacy of FOLFIRI and Paclitaxel Chemotherapy Regimens in the Second Line Treatment of Metastatic Gastric Cancer

ÜRÜN M., GÜNER G., SEZGİN Y., YILMAZ ÜRÜN Y., SAKİN A.
Van Yuzuncu Yil University , cilt.16, sa.2, ss.176-182, 2023 (Hakemli Dergi)

14. ADDITIONAL COST OF OVERWEIGHT IN MEDICATION OF CANCER PATIENTS

ÜRÜN M., SEZGİN Y., YILMAZ ÜRÜN Y., UÇAN A., GÜRCÜ S., TUĞRUL F.
Eskisehir Medical Journal, Eskisehir City Hospital , cilt.4, sa.2, ss.107-110, 2023 (Hakemli Dergi)

15. Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?

Karhan O., Secmeler Ş., Sezgin Y., Ileri S., Yerlikaya H.
Future Oncology , cilt.19, sa.14, ss.983-989, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

16. The Prediction of Overall Survival With The Use of The Sarculator In Operated Soft Tissue Sarcoma of The Extremities: Monocentre Experience

Sezgin Y., Karhan O.
Eastern Journal of Medicine , cilt.28, sa.4, ss.804-809, 2023 (Scopus, TRDizin) identifier identifier

17. Chemotherapy Efficacy and Tolerability in Metastatic Gastric Cancer Patients Aged 75 Years and Older

SEZGİN Y., YILMAZ ÜRÜN Y.
Eurasian Journal of Medical Investigation , cilt.7, sa.4, ss.487-493, 2023 (TRDizin) identifier

18. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy

Ebinç S., Oruç Z., Sezgin Y., Karhan O. u., Bilen E., Yerlikaya H., et al.
Future Oncology , cilt.18, sa.30, ss.3399-3408, 2022 (SCI-Expanded, Scopus) identifier identifier

19. The Relatıonshıp Between Pet Ct And Tumor Features In Patıents Wıth Breast Cancer

SEZGİN Y., KARHAN O., İLERİ S., EBİNÇ S., BİLEN E., ÜRÜN M., et al.
Van Tıp Dergisi , cilt.29, 2022 (TRDizin) identifier

20. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort

Karaağaç M., Sezgin Y., Eryılmaz M. K., Araz M., Kaplan M. A., Artaç M.
Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1657-1666, 2020 (SCI-Expanded, Scopus) identifier identifier
Metrikler

Yayın

20

Yayın (WoS)

11

Yayın (Scopus)

13

Atıf (WoS)

21

H-İndeks (WoS)

3

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Proje

2

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları